{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T17:43:53Z","timestamp":1789494233851,"version":"build-2803163510"},"reference-count":78,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004281","name":"National Science Centre Poland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ijcard.2026.134266","type":"journal-article","created":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T19:59:36Z","timestamp":1772308776000},"page":"134266","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Early development and SGLT2 inhibitor\u2013mediated reversal of coronary microvascular dysfunction in an isoprenaline-induced murine HFpEF model: Insights from multimodal in vivo imaging"],"prefix":"10.1016","volume":"453","author":[{"given":"Grzegorz","family":"Kwiatkowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izabela","family":"Czyzynska-Cichon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna M.","family":"Gdula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Zakrzewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urszula","family":"Tyrankiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Sitek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Jasztal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Ch\u0142opicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2026.134266_bb0005","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/ejhf.1741","article-title":"How to diagnose heart failure with preserved ejection fraction: the HFA\u2013PEFF diagnostic algorithm: a consensus recommendation from the heart failure association (HFA) of the European Society of Cardiology (ESC)","volume":"22","author":"Pieske","year":"2020","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ijcard.2026.134266_bb0010","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nrcardio.2014.83","article-title":"The pathophysiology of heart failure with preserved ejection fraction","volume":"11","author":"Borlaug","year":"2014","journal-title":"Nat. Rev. Cardiol."},{"issue":"19","key":"10.1016\/j.ijcard.2026.134266_bb0015","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1056\/NEJMoa032566","article-title":"Diastolic heart failure \u2014 abnormalities in active relaxation and passive stiffness of the left ventricle","volume":"350","author":"Zile","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2026.134266_bb0020","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1001\/jamacardio.2021.1825","article-title":"Prevalence of coronary artery disease and coronary microvascular dysfunction in patients with heart failure with preserved ejection fraction","volume":"6","author":"Rush","year":"2021","journal-title":"JAMA Cardiol."},{"issue":"10","key":"10.1016\/j.ijcard.2026.134266_bb0025","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1093\/eurheartj\/ehx721","article-title":"Coronary microvascular dysfunction and future risk of heart failure with preserved ejection fraction","volume":"39","author":"Taqueti","year":"2018","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2026.134266_bb0030","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.122.012568","article-title":"Coronary microvascular disease in contemporary clinical practice","volume":"16","author":"Smilowitz","year":"2023","journal-title":"Circ. Cardiovasc. Interv."},{"key":"10.1016\/j.ijcard.2026.134266_bb0035","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1093\/eurheartj\/eht513","article-title":"Coronary microvascular dysfunction: an update","volume":"35","author":"Crea","year":"2014","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2026.134266_bb0040","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.jcin.2024.01.008","article-title":"Prognostic implications of microvascular resistance Reserve in Symptomatic Patients with Intermediate Coronary Stenosis","volume":"17","author":"Lee","year":"2024","journal-title":"JACC Cardiovasc. Interv."},{"key":"10.1016\/j.ijcard.2026.134266_bb0045","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1161\/CIRCULATIONAHA.113.008507","article-title":"Effects of sex on coronary microvascular dysfunction and cardiac outcomes","volume":"129","author":"Murthy","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2026.134266_bb0050","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.hfc.2014.04.008","article-title":"Phenotypic Spectrum of heart failure with preserved ejection fraction","volume":"10","author":"Shah","year":"2014","journal-title":"Heart Fail. Clin."},{"key":"10.1016\/j.ijcard.2026.134266_bb0055","doi-asserted-by":"crossref","unstructured":"K. Srivaratharajah, et al., Reduced myocardial flow in heart failure patients with preserved ejection fraction, Circ. Heart Fail. 9 (7), doi:10.1161\/CIRCHEARTFAILURE.115.002562.","DOI":"10.1161\/CIRCHEARTFAILURE.115.002562"},{"issue":"6","key":"10.1016\/j.ijcard.2026.134266_bb0060","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.jcmg.2021.11.022","article-title":"Prevalence and prognostic significance of microvascular dysfunction in heart failure with preserved ejection fraction","volume":"15","author":"Arnold","year":"2026","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.ijcard.2026.134266_bb0065","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s12968-021-00807-3","article-title":"Cardiovascular magnetic resonance assessment of coronary flow reserve improves risk stratification in heart failure with preserved ejection fraction","volume":"23","author":"Kato","year":"2021","journal-title":"J. Cardiovasc. Magn. Reson."},{"key":"10.1016\/j.ijcard.2026.134266_bb0070","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1161\/CIRCULATIONAHA.116.021884","article-title":"Phenotype-specific treatment of heart failure with preserved ejection fraction: a multiorgan roadmap","volume":"134","author":"Shah","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2026.134266_bb0075","article-title":"Coronary microvascular disease in heart failure with preserved ejection fraction","volume":"13","author":"Sen","year":"2025","journal-title":"Phys. Rep."},{"key":"10.1016\/j.ijcard.2026.134266_bb0080","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","article-title":"A novel paradigm for heart failure with preserved ejection fraction","volume":"62","author":"Paulus","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2026.134266_bb0085","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nrcardio.2014.83","article-title":"The pathophysiology of heart failure with preserved ejection fraction","volume":"11","author":"Borlaug","year":"2014","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.ijcard.2026.134266_bb0090","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1016\/j.jacc.2010.01.054","article-title":"Coronary microvascular reactivity to adenosine predicts adverse outcome in women evaluated for suspected ischemia","volume":"55","author":"Pepine","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2026.134266_bb0095","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41401-023-01152-0","article-title":"Animal models of heart failure with preserved ejection fraction (HFpEF): from metabolic pathobiology to drug discovery","volume":"45","author":"Gao","year":"2024","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ijcard.2026.134266_bb0100","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1161\/CIRCRESAHA.122.320257","article-title":"Heart failure with preserved ejection fraction: heterogeneous syndrome, diverse preclinical models","volume":"130","author":"Roh","year":"2022","journal-title":"Circ. Res."},{"issue":"14","key":"10.1016\/j.ijcard.2026.134266_bb0105","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1093\/cvr\/cvaf174","article-title":"Defining HFpEF in rodents: a systematic review","volume":"121","author":"Yamen","year":"2025","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.ijcard.2026.134266_bb0110","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3389\/fcvm.2019.00100","article-title":"Isoproterenol-induced cardiac diastolic dysfunction in mice: a systems genetics analysis","volume":"6","author":"Wang","year":"2019","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.ijcard.2026.134266_bb0115","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1177\/0267659108100708","article-title":"Comparison of isoproterenol and dobutamine in the induction of cardiac hypertrophy and fibrosis","volume":"23","author":"Anderson","year":"2008","journal-title":"Perfusion"},{"key":"10.1016\/j.ijcard.2026.134266_bb0120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0091877","article-title":"Isoproterenol induces vascular oxidative stress and endothelial dysfunction via a Gi\u03b1-coupled \u03b22-adrenoceptor signaling pathway","volume":"9","author":"Davel","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ijcard.2026.134266_bb0125","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0008-6363(97)00212-5","article-title":"Development of heart failure following isoproterenol administration in the rat: role of the renin\u2013angiotensin system","volume":"37","author":"Grimm","year":"1998","journal-title":"Cardiovasc. Res."},{"issue":"2","key":"10.1016\/j.ijcard.2026.134266_bb0130","doi-asserted-by":"crossref","first-page":"10006","DOI":"10.35534\/fibrosis.2023.10006","article-title":"The severity of isoproterenol-induced myocardial fibrosis and related dysfunction in mice is strain-dependent","volume":"1","author":"Wang","year":"2023","journal-title":"Fibrosis"},{"key":"10.1016\/j.ijcard.2026.134266_bb0135","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1007\/s10495-013-0843-5","article-title":"Isoproterenol instigates cardiomyocyte apoptosis and heart failure via AMPK inactivation-mediated endoplasmic reticulum stress","volume":"18","author":"Zhuo","year":"2013","journal-title":"Apoptosis"},{"issue":"37","key":"10.1016\/j.ijcard.2026.134266_bb0140","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"McDonagh","year":"2026","journal-title":"Eur Heart J."},{"key":"10.1016\/j.ijcard.2026.134266_bb0145","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s12933-022-01607-4","article-title":"Dapagliflozin improves myocardial flow reserve in patients with type 2 diabetes: the DAPAHEART trial: a preliminary report","volume":"21","author":"Leccisotti","year":"2022","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.ijcard.2026.134266_bb0150","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s13300-023-01491-5","article-title":"Dapagliflozin-induced myocardial flow reserve improvement is not associated with HDL ability to stimulate endothelial nitric oxide production","volume":"15","author":"Capece","year":"2024","journal-title":"Diabetes Ther."},{"key":"10.1016\/j.ijcard.2026.134266_bb0155","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1161\/CIRCRESAHA.116.309492","article-title":"Resolving lipid mediators Maresin 1 and Resolvin D2 prevent Atheroprogression in mice","volume":"119","author":"Viola","year":"2016","journal-title":"Circ. Res."},{"key":"10.1016\/j.ijcard.2026.134266_bb0160","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1161\/CIRCULATIONAHA.116.021894","article-title":"Resolvin D2 enhances Postischemic revascularization while resolving inflammation","volume":"134","author":"Zhang","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2026.134266_bb0165","doi-asserted-by":"crossref","first-page":"59","DOI":"10.33696\/cardiology.5.055","article-title":"Investigating the Hormetic role of Resolvin D2 in atherosclerotic cardiovascular disease: pathways to biomarker recognition for Resolvins?","volume":"5","author":"Omarjee","year":"2024","journal-title":"J. Clin. Cardiol."},{"key":"10.1016\/j.ijcard.2026.134266_bb0170","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1096\/fj.14-265363","article-title":"Systemic delivery of proresolving lipid mediators resolvin D2 and maresin 1 attenuates intimal hyperplasia in mice","volume":"29","author":"Akagi","year":"2015","journal-title":"FASEB J."},{"key":"10.1016\/j.ijcard.2026.134266_bb0175","doi-asserted-by":"crossref","first-page":"4192","DOI":"10.1096\/fj.201600144RR","article-title":"D-series resolvins inhibit murine abdominal aortic aneurysm formation and increase M2 macrophage polarization","volume":"30","author":"Pope","year":"2016","journal-title":"FASEB J."},{"key":"10.1016\/j.ijcard.2026.134266_bb0180","doi-asserted-by":"crossref","first-page":"1277065","DOI":"10.3389\/fphys.2023.1277065","article-title":"Enhanced central sympathetic tone induces heart failure with preserved ejection fraction (HFpEF) in rats","volume":"14","author":"Nandi","year":"2023","journal-title":"Front. Physiol."},{"issue":"3","key":"10.1016\/j.ijcard.2026.134266_bb0185","first-page":"31","article-title":"Isoproterenol induces in vivo functional and metabolic abnormalities; similar to those found in the infarcted rat heart","volume":"60","author":"Heather","year":"2009","journal-title":"J Physiol Pharmacol."},{"key":"10.1016\/j.ijcard.2026.134266_bb0190","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1161\/01.HYP.0000192651.06674.3f","article-title":"Lack of inducible NO synthase reduces oxidative stress and enhances cardiac response to isoproterenol in mice with deoxycorticosterone acetate\u2013salt hypertension","volume":"46","author":"Sun","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.ijcard.2026.134266_bb0195","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1016\/j.nano.2016.05.002","article-title":"Preventive effects of simvastatin nanoliposome on isoproterenol-induced cardiac remodeling in mice","volume":"12","author":"Tuerdi","year":"2016","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"10.1016\/j.ijcard.2026.134266_bb0200","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/jcmm.15937","article-title":"Type 2 MI induced by a single high dose of isoproterenol in C57BL\/6J mice triggers a persistent adaptive immune response against the heart","volume":"25","author":"Forte","year":"2021","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.ijcard.2026.134266_bb0205","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1161\/HYPERTENSIONAHA.119.12956","article-title":"Characterization of myocardial microstructure and function in an experimental model of isolated subendocardial damage","volume":"74","author":"Beyhoff","year":"2019","journal-title":"Hypertension"},{"key":"10.1016\/j.ijcard.2026.134266_bb0210","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.033596","article-title":"Impact of coronary microvascular dysfunction on functional left ventricular remodeling and diastolic dysfunction","volume":"13","author":"Aldujeli","year":"2024","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.ijcard.2026.134266_bb0215","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00395-020-0778-2","article-title":"Perturbations in myocardial perfusion and oxygen balance in swine with multiple risk factors: a novel model of ischemia and no obstructive coronary artery disease","volume":"115","author":"Van De Wouw","year":"2020","journal-title":"Basic Res. Cardiol."},{"key":"10.1016\/j.ijcard.2026.134266_bb0220","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1161\/01.HYP.29.2.551","article-title":"Mechanisms of coronary flow reserve impairment in human hypertension: an integrated approach by transthoracic and transesophageal echocardiography","volume":"29","author":"Koz\u00e0kov\u00e0","year":"1997","journal-title":"Hypertension"},{"key":"10.1016\/j.ijcard.2026.134266_bb0225","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1016\/j.jacc.2018.09.042","article-title":"Coronary microvascular disease pathogenic mechanisms and therapeutic options","volume":"72","author":"Taqueti","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2026.134266_bb0230","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.995216","article-title":"Empagliflozin inhibits coronary microvascular dysfunction and reduces cardiac pericyte loss in db\/db mice","volume":"9","author":"Tu","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.ijcard.2026.134266_bb0235","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9092880","article-title":"Coronary microvascular dysfunction","volume":"9","author":"Vancheri","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ijcard.2026.134266_bb0240","doi-asserted-by":"crossref","first-page":"1070935","DOI":"10.3389\/fcvm.2022.1070935","article-title":"Vascular dysfunction in HFpEF: potential role in the development, maintenance, and progression of the disease","volume":"9","author":"Saavedra-Alvarez","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.ijcard.2026.134266_bb0245","doi-asserted-by":"crossref","DOI":"10.1093\/ehjopen\/oead129","article-title":"Pericyte loss initiates microvascular dysfunction in the development of diastolic dysfunction","volume":"4","author":"Simmonds","year":"2023","journal-title":"Eur. Heart J. Open"},{"key":"10.1016\/j.ijcard.2026.134266_bb0250","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1161\/ATVBAHA.121.317319","article-title":"Increased capillary permeability in heart induces diastolic dysfunction independently of inflammation, fibrosis, or cardiomyocyte dysfunction","volume":"42","author":"Abelanet","year":"2022","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.ijcard.2026.134266_bb0255","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24054321","article-title":"Molecular mechanisms and therapeutic implications of endothelial dysfunction in patients with heart failure","volume":"24","author":"Tsigkou","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ijcard.2026.134266_bb0260","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00395-020-0798-y","article-title":"Microvascular and lymphatic dysfunction in HFpEF and its associated comorbidities","volume":"115","author":"Cuijpers","year":"2020","journal-title":"Basic Res. Cardiol."},{"key":"10.1016\/j.ijcard.2026.134266_bb0265","doi-asserted-by":"crossref","DOI":"10.1002\/nbm.5105","article-title":"Retrospectively gated ultrashort-echo-time MRI T1 mapping reveals compromised pulmonary microvascular NO-dependent function in a murine model of acute lung injury","volume":"37","author":"Kwiatkowski","year":"2024","journal-title":"NMR Biomed."},{"key":"10.1016\/j.ijcard.2026.134266_bb0270","doi-asserted-by":"crossref","first-page":"18915","DOI":"10.1038\/s41598-021-98401-1","article-title":"MRI-based in vivo detection of coronary microvascular dysfunction before alterations in cardiac function induced by short-term high-fat diet in mice","volume":"11","author":"Kwiatkowski","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ijcard.2026.134266_bb0275","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1097\/MS9.0000000000002971","article-title":"Heart failure and microvascular dysfunction: an in-depth review of mechanisms, diagnostic strategies, and innovative therapies","volume":"87","author":"Singh","year":"2025","journal-title":"Ann. Med. Surg."},{"key":"10.1016\/j.ijcard.2026.134266_bb0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106931","article-title":"Modulation of the nitric oxide\/cGMP pathway in cardiac contraction and relaxation: potential role in heart failure treatment","volume":"196","author":"Mollace","year":"2023","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ijcard.2026.134266_bb0285","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/s41586-019-1100-z","article-title":"Nitrosative stress drives heart failure with preserved ejection fraction","volume":"568","author":"Schiattarella","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.ijcard.2026.134266_bb0290","doi-asserted-by":"crossref","first-page":"15200","DOI":"10.3390\/ijms242015200","article-title":"Dysfunctional and dysregulated nitric oxide synthases in cardiovascular disease: mechanisms and therapeutic potential","volume":"24","author":"Roy","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ijcard.2026.134266_bb0295","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1093\/eurheartj\/ehab653","article-title":"Untangling the pathophysiologic link between coronary microvascular dysfunction and heart failure with preserved ejection fraction","volume":"42","author":"Sinha","year":"2021","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2026.134266_bb0300","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1177\/0003319720979243","article-title":"Novel insights regarding nitric oxide and cardiovascular diseases","volume":"72","author":"Infante","year":"2021","journal-title":"Angiology"},{"key":"10.1016\/j.ijcard.2026.134266_bb0305","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jchf.2015.10.007","article-title":"Myocardial microvascular inflammatory endothelial activation in heart failure with preserved ejection fraction","volume":"4","author":"Franssen","year":"2016","journal-title":"JACC Heart Fail."},{"issue":"4","key":"10.1016\/j.ijcard.2026.134266_bb0310","article-title":"Preservation of left ventricle peak and mean pulse flow blood velocity despite progressive deterioration of cardiac function in a chronic heart failure murine model","volume":"72","author":"Tyrankiewicz","year":"2021","journal-title":"J. Physiol. Pharmacol."},{"key":"10.1016\/j.ijcard.2026.134266_bb0315","doi-asserted-by":"crossref","DOI":"10.1002\/nbm.4123","article-title":"Extended quantitative dynamic contrast-enhanced cardiac perfusion imaging in mice using accelerated data acquisition and spatially distributed, two-compartment exchange modeling","volume":"32","author":"Kwiatkowski","year":"2019","journal-title":"NMR Biomed."},{"key":"10.1016\/j.ijcard.2026.134266_bb0320","doi-asserted-by":"crossref","DOI":"10.1002\/nbm.4593","article-title":"Quantitative myocardial first-pass perfusion imaging of CO2 -induced vasodilation in rats","volume":"34","author":"Kwiatkowski","year":"2021","journal-title":"NMR Biomed."},{"key":"10.1016\/j.ijcard.2026.134266_bb0325","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2026.134266_bb0330","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1161\/CIRCULATIONAHA.122.059785","article-title":"Empagliflozin for heart failure with preserved left ventricular ejection fraction with and without diabetes","volume":"146","author":"Filippatos","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2026.134266_bb0335","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1096\/fj.08-112201","article-title":"Atherosclerosis: evidence for impairment of resolution of vascular inflammation governed by specific lipid mediators","volume":"22","author":"Merched","year":"2008","journal-title":"FASEB J."},{"key":"10.1016\/j.ijcard.2026.134266_bb0340","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.jcmg.2020.07.042","article-title":"Empagliflozin ameliorates diastolic dysfunction and left ventricular fibrosis\/stiffness in nondiabetic heart failure","volume":"14","author":"Santos-Gallego","year":"2021","journal-title":"JACC Cardiovasc. Imaging"},{"key":"10.1016\/j.ijcard.2026.134266_bb0345","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12933-019-0820-6","article-title":"SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic Ob\/Ob\u2212\/\u2212 mice","volume":"18","author":"Adingupu","year":"2019","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.ijcard.2026.134266_bb0350","article-title":"Sodium glucose co-transporter 2 inhibitors ameliorate endothelium barrier dysfunction induced by cyclic stretch through inhibition of reactive oxygen species","volume":"22","author":"Li","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ijcard.2026.134266_bb0355","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12933-022-01480-1","article-title":"Direct cardiac effects of SGLT2 inhibitors","volume":"21","author":"Chen","year":"2022","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.ijcard.2026.134266_bb0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2025.117967","article-title":"Sodium-glucose co-transporters (SGLT2) inhibitors prevent lipid droplets formation in vascular inflammation or lipid overload by SGLT2-independent mechanism","volume":"185","author":"Chorazy","year":"2025","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ijcard.2026.134266_bb0365","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1161\/CIRCULATIONAHA.122.061688","article-title":"Sodium glucose Cotransporter-2 inhibitor Empagliflozin reduces infarct size independently of sodium glucose Cotransporter-2","volume":"147","author":"Chen","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2026.134266_bb0370","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2020.165807","article-title":"Empagliflozin improves left ventricular diastolic function of db\/db mice","volume":"1866","author":"Moellmann","year":"2020","journal-title":"Biochim. Biophys. Acta (BBA) - Mol. Basis Dis."},{"key":"10.1016\/j.ijcard.2026.134266_bb0375","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1007\/s00125-018-4670-7","article-title":"SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review","volume":"61","author":"Verma","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.ijcard.2026.134266_bb0380","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1016\/j.jacc.2020.12.065","article-title":"Therapeutic potential of ketone bodies for patients with cardiovascular disease","volume":"77","author":"Yurista","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2026.134266_bb0385","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112515","article-title":"Empagliflozin reduces oxidative stress through inhibition of the novel inflammation\/NHE\/[Na+]c\/ROS-pathway in human endothelial cells","volume":"146","author":"Uthman","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ijcard.2026.134266_bb0390","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/s42003-023-04663-y","article-title":"The SGLT2 inhibitor empagliflozin improves cardiac energy status via mitochondrial ATP production in diabetic mice","volume":"6","author":"Choi","year":"2023","journal-title":"Commun. Biol."}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527326001142?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527326001142?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T22:14:31Z","timestamp":1777500871000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527326001142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":78,"alternative-id":["S0167527326001142"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2026.134266","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Early development and SGLT2 inhibitor\u2013mediated reversal of coronary microvascular dysfunction in an isoprenaline-induced murine HFpEF model: Insights from multimodal in vivo imaging","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2026.134266","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"134266"}}